###begin article-title 0
###xml 8 12 8 12 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LKB1</italic>
Somatic LKB1 Mutations Promote Cervical Cancer Progression
###end article-title 0
###begin p 1
Conceived and designed the experiments: SW DK JS KKW DHC. Performed the experiments: SW TG EA MCL CC TB TS. Analyzed the data: SW TG EA MCL CC TB TS NS NB DK JS KKW DHC. Contributed reagents/materials/analysis tools: DSM JS KKW DHC. Wrote the paper: DHC.
###end p 1
###begin p 2
###xml 698 702 698 702 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LKB1</italic>
###xml 1149 1156 1149 1156 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 1158 1162 1158 1162 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LKB1</italic>
###xml 1300 1304 1300 1304 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LKB1</italic>
###xml 1357 1361 1357 1361 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LKB1</italic>
###xml 1380 1381 1380 1381 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 1452 1456 1452 1456 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LKB1</italic>
###xml 1634 1638 1634 1638 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LKB1</italic>
###xml 0 21 <span type="species:ncbi:10566">Human Papilloma Virus</span>
###xml 23 26 <span type="species:ncbi:10566">HPV</span>
###xml 92 95 <span type="species:ncbi:10566">HPV</span>
###xml 162 167 <span type="species:ncbi:9606">women</span>
###xml 1082 1087 <span type="species:ncbi:9606">human</span>
###xml 1286 1294 <span type="species:ncbi:9606">patients</span>
###xml 1343 1351 <span type="species:ncbi:9606">patients</span>
###xml 1569 1572 <span type="species:ncbi:10566">HPV</span>
Human Papilloma Virus (HPV) is the etiologic agent for cervical cancer. Yet, infection with HPV is not sufficient to cause cervical cancer, because most infected women develop transient epithelial dysplasias that spontaneously regress. Progression to invasive cancer has been attributed to diverse host factors such as immune or hormonal status, as no recurrent genetic alterations have been identified in cervical cancers. Thus, the pressing question as to the biological basis of cervical cancer progression has remained unresolved, hampering the development of novel therapies and prognostic tests. Here we show that at least 20% of cervical cancers harbor somatically-acquired mutations in the LKB1 tumor suppressor. Approximately one-half of tumors with mutations harbored single nucleotide substitutions or microdeletions identifiable by exon sequencing, while the other half harbored larger monoallelic or biallelic deletions detectable by multiplex ligation probe amplification (MLPA). Biallelic mutations were identified in most cervical cancer cell lines; HeLa, the first human cell line, harbors a homozygous 25 kb deletion that occurred in vivo. LKB1 inactivation in primary tumors was associated with accelerated disease progression. Median survival was only 13 months for patients with LKB1-deficient tumors, but >100 months for patients with LKB1-wild type tumors (P = 0.015, log rank test; hazard ratio = 0.25, 95% CI = 0.083 to 0.77). LKB1 is thus a major cervical tumor suppressor, demonstrating that acquired genetic alterations drive progression of HPV-induced dysplasias to invasive, lethal cancers. Furthermore, LKB1 status can be exploited clinically to predict disease recurrence.
###end p 2
###begin title 3
Introduction
###end title 3
###begin p 4
###xml 206 209 206 209 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005137-Schoell1">[1]</xref>
###xml 425 428 425 428 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005137-Steben1">[2]</xref>
###xml 430 433 430 433 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005137-Ellenson1">[3]</xref>
###xml 675 678 675 678 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005137-Steben1">[2]</xref>
###xml 724 731 724 731 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in situ</italic>
###xml 762 763 762 763 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">H</underline>
###xml 773 774 773 774 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S</underline>
###xml 782 783 782 783 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">I</underline>
###xml 798 799 798 799 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">L</underline>
###xml 817 820 817 820 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005137-Ellenson1">[3]</xref>
###xml 822 825 822 825 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005137-Crum1">[4]</xref>
###xml 827 830 827 830 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005137-Arbyn1">[5]</xref>
###xml 975 978 975 978 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005137-Steben1">[2]</xref>
###xml 1241 1244 1241 1244 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005137-Steben1">[2]</xref>
###xml 1378 1381 1378 1381 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005137-Dall1">[6]</xref>
###xml 1628 1631 1628 1631 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005137-zurHausen1">[7]</xref>
###xml 200 205 <span type="species:ncbi:9606">women</span>
###xml 281 302 <span type="species:ncbi:10566">Human Papilloma Virus</span>
###xml 304 307 <span type="species:ncbi:10566">HPV</span>
###xml 365 368 <span type="species:ncbi:10566">HPV</span>
###xml 462 465 <span type="species:ncbi:10566">HPV</span>
###xml 847 850 <span type="species:ncbi:10566">HPV</span>
###xml 924 927 <span type="species:ncbi:10566">HPV</span>
###xml 1273 1276 <span type="species:ncbi:10566">HPV</span>
###xml 1444 1447 <span type="species:ncbi:10566">HPV</span>
###xml 1549 1552 <span type="species:ncbi:10566">HPV</span>
Cervical cancer is among the most common cancers worldwide, with over 500,000 new cases and 250,000 deaths each year. In the developing world, cervical cancer is the leading cause of cancer deaths in women [1]. Infection of cervical epithelial cells with a transmissible agent-the Human Papilloma Virus (HPV)-is necessary for the development of cervical cancer, as HPV DNA sequences are detectable in >99% of cervical tumors [2], [3]. Infection with "high-risk" HPV subtypes initiates tumor progression by abrogating cell cycle control and apoptosis checkpoints through the viral oncoproteins E6 and E7, which inactivate the p53 and RB tumor suppressor pathways respectively [2]. This leads to the formation of noninvasive (in situ) cervical dysplasias known as High-grade Squamous Intraepithelial Lesions, or HSILs) [3], [4], [5]. However, these HPV-induced dysplasias are asymptomatic and most regress, demonstrating that HPV is not sufficient to result in cervical cancer [2]. The progression of cervical dysplasias to invasive, lethal cervical cancers has been attributed to diverse factors such as immune, hormonal, and nutritional status, or co-infection with other sexually-transmitted agents, but supporting data have been equivocal [2]. Insertional mutagenesis by HPV is another proposed tumor-promoting mechanism, but recent studies have not supported this hypothesis [6]. No common, recurring genetic alterations that cooperate with HPV to promote cervical cancer progression have been identified since Harald Zur Hausen first identified HPV as the causal transmissible agent of cervical cancer over thirty years ago [7]. Thus, the pressing question as to the biological basis of cervical cancer progression has remained unresolved.
###end p 4
###begin p 5
###xml 26 30 26 30 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LKB1</italic>
###xml 61 66 61 66 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">STK11</italic>
###xml 265 268 265 268 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005137-Alessi1">[8]</xref>
###xml 274 278 274 278 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LKB1</italic>
###xml 370 373 370 373 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005137-Ji1">[9]</xref>
###xml 375 379 375 379 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005137-Matsumoto1">[10]</xref>
###xml 397 401 397 401 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LKB1</italic>
###xml 487 491 487 491 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Lkb1</italic>
###xml 595 599 595 599 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005137-Contreras1">[11]</xref>
###xml 601 605 601 605 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005137-Gurumurthy1">[12]</xref>
###xml 641 645 641 645 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LKB1</italic>
###xml 508 513 <span type="species:ncbi:10090">mouse</span>
Germline mutations in the LKB1 tumor suppressor gene (a.k.a. STK11) result in Peutz-Jeghers Syndrome (PJS), a hereditary condition characterized by benign gastrointestinal polyps and an elevated (>15x) risk of malignant epithelial cancers at various anatomic sites [8]. The LKB1 gene was recently shown to undergo somatic mutation in >30% of non-small cell lung cancers [9], [10], suggesting that LKB1 may play a broad tumor suppressor role. This, combined with our recent findings that Lkb1 inactivation in mouse uterus or epidermis promotes aggressive endometrial and squamous cell carcinomas [11], [12] prompted us to explore the role of LKB1 in cervical cancer progression.
###end p 5
###begin title 6
Results
###end title 6
###begin title 7
###xml 21 25 21 25 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LKB1</italic>
Somatically-Acquired LKB1 Mutations are Common in Cervical Cancer Across Histologic Subtypes
###end title 7
###begin p 8
###xml 18 22 18 22 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LKB1</italic>
###xml 134 141 134 141 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0005137-t001">Table 1</xref>
###xml 143 151 143 151 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0005137.s002">Table S1</xref>
###xml 153 162 153 162 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005137-g001">Figure 1A</xref>
###xml 289 298 289 298 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">bona fide</italic>
###xml 656 660 656 660 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005137-Hearle1">[13]</xref>
###xml 662 666 662 666 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005137-Boudeau1">[14]</xref>
###xml 668 672 668 672 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005137-Nezu1">[15]</xref>
###xml 895 904 895 904 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">c.2077C&gt;G</italic>
###xml 993 997 993 997 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005137-Launonen1">[16]</xref>
###xml 1039 1043 1039 1043 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LKB1</italic>
###xml 1105 1114 1105 1114 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005137-g001">Figure 1B</xref>
###xml 1116 1124 1116 1124 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0005137.s002">Table S1</xref>
Sequencing of the LKB1 gene in primary cervical tumors identified somatically-acquired (non-germline) mutations in 8/86 (9%) samples (Table 1, Table S1, Figure 1A). In addition to other findings presented below, several observations argue that these mutations are as a group inactivating, bona fide cancer-causing mutations. First, 4/8 tumors harbored nonsense mutations, deletions, or insertions resulting in frameshift and premature termination. The remaining four tumors harbored kinase domain mutations in residues conserved in vertebrate species, and two of these tumors harbored a known PJS mutation (p.Arg304Trp) that abrogates LKB1 kinase activity [13], [14], [15]. Lastly, only 1/9 coding variants were of germline origin, vs. 7/7 noncoding variants, a difference that is statistically significant (p = 0.0014, Fisher's Exact Test) particularly since the single germline coding variant c.2077C>G (p.Phe354Leu) is a known non-pathological neutral variant present in normal individuals [16]. Sequencing also identified a homozygous LKB1 kinase domain mutation in the cervical cancer cell line C4I (Figure 1B, Table S1).
###end p 8
###begin title 9
###xml 35 39 35 39 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LKB1</italic>
Somatic mutations and deletions of LKB1 in cervical tumors.
###end title 9
###begin p 10
###xml 388 392 388 392 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LKB1</italic>
###xml 520 524 520 524 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LKB1</italic>
###xml 751 755 727 731 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LKB1</italic>
###xml 115 122 <span type="species:ncbi:9606">patient</span>
###xml 133 138 <span type="species:ncbi:9606">human</span>
(A) Representative chromatograms of primary tumors. (B) C4I cell line. Lower panels, control DNA samples from each patient (for C4I, human peripheral leukocyte DNA). Wild-type sequences are shown below. Chromatograms represent forward strand except case #41 where reverse complement is shown to more clearly illustrate the deletion. Mutations are heterozygous except where indicated. (C) LKB1 deletions in primary cervical tumors by MLPA. Bars = relative signal intensity per probe. Sixteen probes (black) correspond to LKB1 locus on chromosome 19. Probe identifiers shown below. Probes 0.9M5' and 0.6M5' are approximately900 and 600 kb 5' of locus (telomeric), while 10M3' is approximately10000 kb 3' (centromeric); remaining 13 probes correspond to LKB1 noncoding/coding exons. White bars correspond to randomly selected probes from other chromosomes.
###end p 10
###begin title 11
###xml 22 30 <span type="species:ncbi:9606">Patients</span>
Characteristics of 86 Patients in the Study Population.
###end title 11
###begin p 12
###xml 27 31 27 31 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LKB1</italic>
###xml 112 120 112 120 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0005137.s002">Table S1</xref>
###xml 122 131 122 131 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005137-g001">Figure 1A</xref>
###xml 282 286 282 286 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LKB1</italic>
###xml 471 475 471 475 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LKB1</italic>
###xml 503 511 503 511 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0005137.s002">Table S1</xref>
###xml 513 522 513 522 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005137-g001">Figure 1C</xref>
###xml 638 647 638 647 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005137-g001">Figure 1C</xref>
###xml 894 902 894 902 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0005137.s002">Table S1</xref>
###xml 1067 1071 1067 1071 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LKB1</italic>
###xml 1110 1114 1110 1114 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LKB1</italic>
###xml 1141 1144 1141 1144 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005137-Ji1">[9]</xref>
###xml 1146 1150 1146 1150 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005137-Bardeesy1">[17]</xref>
###xml 1328 1332 1328 1332 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LKB1</italic>
###xml 1502 1506 1502 1506 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LKB1</italic>
###xml 1688 1692 1688 1692 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005137-Young1">[18]</xref>
###xml 1700 1704 1700 1704 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LKB1</italic>
###xml 1931 1939 1931 1939 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005137-g002">Figure 2</xref>
###xml 1941 1949 1941 1949 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0005137.s002">Table S1</xref>
###xml 1951 1954 1951 1954 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005137-Crum1">[4]</xref>
###xml 348 353 <span type="species:ncbi:9606">human</span>
###xml 940 945 <span type="species:ncbi:9606">human</span>
###xml 950 955 <span type="species:ncbi:10090">mouse</span>
Although one small (26 bp) LKB1 deletion representing a complete loss-of-function was identified by sequencing (Table S1, Figure 1A), larger deletions would have been missed. To systematically screen for deletions, multiplex ligation-dependent probe amplification (MLPA) for all 10 LKB1 exons and three flanking probes was employed. Whereas normal human DNA control samples (n = 3) consistently showed equivalent signal strengths for all probes, MLPA identified distinct LKB1 deletions in 10/86 tumors (Table S1, Figure 1C). In five tumors, deletions appeared to be homozygous because signals from contiguous probes were reduced by >50% (Figure 1C, cases 60 and 22); residual signal in these cases likely reflects stromal contamination. Of tumors with apparent heterozygous deletions, one also contained a significant mutation identified by sequencing (Case 41, which harbors a 26 bp deletion, Table S1). These findings are consistent with human and mouse studies showing that although loss of the second allele can accelerate tumor progression, mutation of a single LKB1 allele is by itself tumorigenic (i.e. LKB1 can be haploinsufficient) [9], [17]. However, it is also possible that some mutations went undetected, or that stromal contamination led to an underestimation of homozygosity. In summary, biologically-significant LKB1 mutations including deletions characterize at least 20% (17/86) of invasive cervical cancers. Only one case in our study (case 20, which harbored a somatically-acquired LKB1 mutation) was diagnosed as a minimal-deviation adenocarcinoma (MDA), a rare, extremely well-differentiated variant of cervical adenocarcinoma associated with Peutz-Jeghers Syndrome [18]. Thus, LKB1 mutations in cervical cancers were not limited to this rare histologic subtype but were present across the principal histologic subtypes of cervical cancer-adenocarcinoma, squamous cell carcinoma, and adenosquamous carcinoma (Figure 2, Table S1) [4].
###end p 12
###begin title 13
###xml 0 4 0 4 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LKB1</italic>
LKB1 mutations occur in each of the principal histologic subtypes of cervical cancer.
###end title 13
###begin p 14
###xml 43 47 43 47 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LKB1</italic>
###xml 289 293 289 293 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LKB1</italic>
###xml 311 315 311 315 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LKB1</italic>
###xml 417 421 417 421 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LKB1</italic>
(A) Histology of representative cases with LKB1 mutations (SCC = squamous cell carcinoma; Adeno = adenocarcinoma; AdenoSq = adenosquamous carcinoma; MDA = minimal deviation adenocarcinoma). Scale bar = 20 microns. (B) Relative distribution of the three principal histologic subtypes among LKB1-mutant (red) vs. LKB1-wild type (black) cases (totals = 100%) shows that the histologic spectrum is virtually identical in LKB1 null vs. wild-type tumors.
###end p 14
###begin title 15
###xml 13 17 13 17 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LKB1</italic>
Deletions of LKB1 Characterize Most Cervical Cancer Cell Lines
###end title 15
###begin p 16
###xml 224 228 224 228 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LKB1</italic>
###xml 406 410 406 410 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LKB1</italic>
###xml 457 466 457 466 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005137-g003">Figure 3A</xref>
###xml 485 494 485 494 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005137-g003">Figure 3A</xref>
###xml 544 548 544 548 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LKB1</italic>
###xml 701 710 701 710 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005137-g001">Figure 1B</xref>
###xml 712 720 712 720 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0005137.s002">Table S1</xref>
###xml 825 829 825 829 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LKB1</italic>
###xml 841 850 841 850 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005137-g003">Figure 3B</xref>
###xml 949 958 949 958 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005137-g003">Figure 3C</xref>
###xml 991 995 991 995 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LKB1</italic>
###xml 1073 1077 1073 1077 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LKB1</italic>
###xml 1265 1269 1265 1269 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LKB1</italic>
###xml 1377 1381 1377 1381 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LKB1</italic>
Primary tumors are clonally diverse and contain variable numbers of cells such as fibroblasts and lymphocytes that can obscure these and other analyses. To overcome this limitation and gain further insights into the role of LKB1 in cervical cancer, a panel of seven cervical cancer cell lines (HeLa, HT3, SiHa, MS751, CaSki, C33a, and C4I) was analyzed. Strikingly, five of these seven cell lines harbored LKB1 deletions, as did the HeLa derivative HeLaS3 (Figure 3A). Only the CaSki (Figure 3A) and C33a (not shown) cell lines did not exhibit LKB1 deletions. The majority (4/7) harbored homozygous deletions, while the one cell line with a heterozygous deletion (C4I) also harbored a point mutation (Figure 1B, Table S1) rationalizing the loss of heterozygosity for this mutation in C4I. Southern analysis confirmed loss of LKB1 sequences (Figure 3B) and as expected, LKB1 protein was undetectable in the cell lines harboring homozygous deletions (Figure 3C). This frequent homozygosity of LKB1 mutations in cell lines further underscores the pathogenetic significance of LKB1 loss in cervical cancer. Although the number of lines available and hence analyzed was small, it is notable that the majority of cervical cancer cell lines harbored definitive bialleleic LKB1 mutations. It is also possible that the establishment of primary cervical tumor cultures is biased towards LKB1-deficient tumors.
###end p 16
###begin title 17
###xml 11 15 11 15 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LKB1</italic>
Homozygous LKB1 deletions occur in majority of cervical cancer cell lines.
###end title 17
###begin p 18
###xml 14 22 14 22 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005137-g001">Figure 1</xref>
###xml 380 387 <span type="species:ncbi:9606">patient</span>
(A) MLPA; see Figure 1 for probe details. HeLa, MS751, SiHa, and HT3 (and HeLa subclone HeLaS3) contain distinctive homozygous deletions. C4I harbors a monoallelic deletion, as evidenced by contiguous probes with half-intensity signals. (B) Southern analysis of control DNA, above cell lines, C33 (no deletion by MLPA) and HPV16/E6E7-immortalized endocervical cells from a normal patient (Endo = End1/E6E7; ATCC #CRL-2615). (C) Western analysis. LKB1 protein is undetectable in lines harboring homozygous deletions and decreased by approximately50% in C4I, consistent with monoallelic loss.
###end p 18
###begin p 19
###xml 73 77 73 77 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005137-Tiainen1">[19]</xref>
###xml 83 87 83 87 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LKB1</italic>
###xml 248 252 248 252 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005137-Esteller1">[20]</xref>
###xml 287 291 287 291 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LKB1</italic>
###xml 473 477 473 477 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LKB1</italic>
###xml 610 614 610 614 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005137-Tiainen1">[19]</xref>
###xml 636 639 636 639 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005137-Ji1">[9]</xref>
###xml 746 750 746 750 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LKB1</italic>
The absence of LKB1 protein in HeLa and HeLaS3 has been previously noted [19]. The LKB1 gene is associated with a prominent CpG island, and the lack of LKB1 protein and mRNA in HeLa cells had been previously attributed to promoter hypermethylation [20]. However, we found no evidence of LKB1 hypermethylation by methylation-specific PCR in any cell line or primary tumor samples. To the contrary, our data show that HeLa and other cervical cancer cell lines do not express LKB1 because of homozygous deletions, rather than as a result of epigenetic silencing. Consistent with prior studies carried out in HeLa [19] and other cell lines [9], enforced expression of wild-type LKB1 led to cell cycle arrest and growth inhibition, demonstrating that LKB1 loss in these cell lines is functionally significant (data not shown).
###end p 19
###begin p 20
###xml 118 130 118 130 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005137-g004">Figure 4A, B</xref>
###xml 340 349 340 349 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005137-g004">Figure 4C</xref>
###xml 455 459 443 447 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LKB1</italic>
###xml 498 502 486 490 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SBNO</italic>
To define deletion breakpoints, PCR reactions producing small amplicons (100-200 bp) were designed to span the locus (Figure 4A, B). Scoring (+/-) amplification of each product followed by additional PCR reactions for progressively narrower intervals based on results of the initial scan permitted us to map breakpoints to within a few kb (Figure 4C). Each of the four cell lines harbored a distinct deletion (approximately20-110 kb) removing portions of LKB1 and at most one other flanking locus (SBNO2).
###end p 20
###begin title 21
###xml 0 4 0 4 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LKB1</italic>
LKB1 deletion breakpoints in cervical cancer cell lines.
###end title 21
###begin p 22
###xml 4 8 4 8 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LKB1</italic>
###xml 93 97 93 97 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LKB1</italic>
###xml 467 471 467 471 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LKB1</italic>
###xml 490 497 490 497 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
(A) LKB1 locus (chromosome 19p13.3). (B) 140 kb region (Ensembl50; 1050000-1190000) spanning LKB1 and immediately flanking loci; intervals = 10 kb. (C) Deletion breakpoints for cell lines harboring homozygous deletions. In MS751, deleted sequences are discontinuous as shown, consistent with a more complex rearrangement. Arrows = PCR primers for HeLa specific PCR (400 bp). (D) HeLa specific PCR (400 bp) confirms presence of deletion in HeLaS3. (E) HeLa intragenic LKB1 deletion occurred in vivo. Archival blocks were cored for DNA preparation. Lanes are as follows: (-) control = no template control; tumor = metastatic adrenal deposit; non-tumor = normal adrenal (same tissue block); (+) control = HeLa cell line DNA.
###end p 22
###begin title 23
###xml 30 34 30 34 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LKB1</italic>
###xml 57 64 57 64 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">In Vivo</italic>
Molecular Cloning of the HeLa LKB1 Deletion Junction and In Vivo Origin of the Deletion
###end title 23
###begin p 24
###xml 281 290 281 290 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0005137.s001">Figure S1</xref>
###xml 292 301 292 301 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005137-g004">Figure 4C</xref>
###xml 345 354 345 354 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0005137.s001">Figure S1</xref>
###xml 584 593 584 593 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0005137.s001">Figure S1</xref>
To clone across the HeLa junction, primers flanking the 5' and 3' breakpoints mapped by the above PCR scanning strategy were designed to amplify a specific breakpoint product. A 2.8 kb junctional fragment was cloned and sequenced, confirming the presence of a deletion (24,662 bp, Figure S1, Figure 4C). Both breakpoints lie within Alu repeats (Figure S1), suggesting that inter-Alu homologous recombination produced the deletion. To create an efficient PCR assay for this deletion, primers immediately flanking the repetitive Alu sequences at each breakpoint were designed (400 bp) (Figure S1).
###end p 24
###begin p 25
###xml 59 63 59 63 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005137-Puck1">[21]</xref>
###xml 88 92 88 92 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LKB1</italic>
###xml 103 112 103 112 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005137-g004">Figure 4D</xref>
###xml 138 156 138 156 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">terminus ante quem</italic>
###xml 237 241 237 241 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LKB1</italic>
###xml 257 265 257 265 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 349 353 349 353 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005137-Gey1">[22]</xref>
###xml 609 618 609 618 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005137-g004">Figure 4E</xref>
###xml 643 647 643 647 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LKB1</italic>
###xml 666 673 666 673 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 487 494 <span type="species:ncbi:9606">patient</span>
HeLaS3, a clonal derivative of HeLa first reported in 1955 [21], harbored the identical LKB1 deletion (Figure 4D), establishing 1955 as a terminus ante quem for the origin of the deletion. However, it remained formally possible that the LKB1 deletion arose in vitro following the establishment of HeLa from a primary cervical adenocarcinoma in 1951 [22]. To resolve this question, HeLa tumor DNA was isolated from an archival paraffin-embedded tissue block prepared in the course of the patient's autopsy at the Johns Hopkins Hospital in 1951. A 400 bp HeLa-specific PCR product was amplified from the tumor (Figure 4E), establishing that the LKB1 deletion occurred in vivo.
###end p 25
###begin p 26
###xml 22 26 22 26 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LKB1</italic>
###xml 84 88 84 88 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LKB1</italic>
###xml 180 187 180 187 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 192 200 192 200 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 261 265 261 265 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LKB1</italic>
###xml 385 389 385 389 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LKB1</italic>
###xml 507 511 507 511 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LKB1</italic>
###xml 582 586 582 586 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LKB1</italic>
###xml 639 643 639 643 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LKB1</italic>
###xml 662 670 662 670 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005137-g005">Figure 5</xref>
###xml 745 749 745 749 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LKB1</italic>
###xml 827 831 827 831 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LKB1</italic>
###xml 910 914 910 914 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LKB1</italic>
###xml 994 998 994 998 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LKB1</italic>
###xml 1109 1113 1109 1113 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LKB1</italic>
###xml 51 58 <span type="species:ncbi:9606">patient</span>
###xml 354 362 <span type="species:ncbi:9606">patients</span>
###xml 466 474 <span type="species:ncbi:9606">patients</span>
###xml 568 576 <span type="species:ncbi:9606">patients</span>
###xml 625 633 <span type="species:ncbi:9606">patients</span>
###xml 1164 1172 <span type="species:ncbi:9606">patients</span>
The occurrence of the LKB1 HeLa deletion while the patient was alive suggested that LKB1 inactivation might have contributed to the notoriously aggressive growth of her tumor both in vivo and in vitro (see below and discussion). To explore the possibility that LKB1 mutations influence disease course, progression-free survival curves were generated for patients whose tumors harbored LKB1 mutations identified by sequencing or MLPA (heterozygous or homozygous) and patients whose tumors were wild-type for LKB1. Strikingly, the median survival was only 13 months for patients with LKB1-deficient tumors, but >100 months for patients with LKB1-wild type tumors (Figure 5) (P = 0.015, log-rank test; hazard ratio = 0.25, 95% CI = 0.083 to 0.77). LKB1-deficient tumors were not more advanced at the time of staging, e.g., 28% of LKB1-wild type tumors were initially Stage I (confined to the uterus), vs. 43% for LKB1-deficient tumors, nor of higher grade (i.e. more poorly-differentiated). Thus, LKB1 mutations in cervical tumors confer a stage-for-stage increased risk of recurrence, suggesting that assays of LKB1 status will be of clinical utility in identifying patients at increased risk for disease progression.
###end p 26
###begin title 27
###xml 43 47 43 47 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LKB1</italic>
###xml 62 66 62 66 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LKB1</italic>
###xml 29 37 <span type="species:ncbi:9606">patients</span>
Progression-free survival of patients with LKB1-wild type vs. LKB1-mutant tumors.
###end title 27
###begin p 28
###xml 186 190 186 190 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LKB1</italic>
###xml 43 51 <span type="species:ncbi:9606">patients</span>
###xml 107 115 <span type="species:ncbi:9606">patients</span>
###xml 196 204 <span type="species:ncbi:9606">patients</span>
###xml 239 247 <span type="species:ncbi:9606">Patients</span>
Kaplan-Meier curves show the percentage of patients with disease progression over time. The curves compare patients whose tumors were heterozygous or homozygous for mutations/deletions (LKB1) vs. patients with no mutations/deletions (wt). Patients with >1 follow-up visit were included in the analysis. P value per log-rank test.
###end p 28
###begin title 29
Discussion
###end title 29
###begin p 30
###xml 159 163 159 163 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LKB1</italic>
###xml 304 308 304 308 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LKB1</italic>
###xml 481 485 481 485 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LKB1</italic>
###xml 531 535 531 535 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LKB1</italic>
###xml 568 572 568 572 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005137-Connolly1">[23]</xref>
###xml 692 696 692 696 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LKB1</italic>
###xml 724 728 724 728 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005137-Avizienyte1">[24]</xref>
###xml 795 799 795 799 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LKB1</italic>
###xml 931 935 931 935 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LKB1</italic>
###xml 1048 1051 1036 1039 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005137-Ji1">[9]</xref>
###xml 1150 1154 1138 1142 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LKB1</italic>
Our study is the first to demonstrate that recurrent genetic mutations occur in cervical cancer. An earlier study that examined this question did not identify LKB1 mutations in sporadic cervical cancers, but only minimal deviation adenocarcinomas were analyzed, as the goal of the study was to ascertain LKB1 mutation frequencies in gynecologic malignancies known to be associated with PJS. However, this earlier study, performed prior to the advent of MLPA, identified LOH of the LKB1 19p13.3 region in 3/8 cases, suggesting that LKB1 deletions may have been present [23]. Another study where 26 cervical tumors were analyzed by single-strand conformational polymorphism analysis identified LKB1 mutations in only one case [24]. However, this study also greatly underestimated the frequency of LKB1 mutations in lung cancer, now known to occur in >20% of cases. The advent of MLPA now facilitates the definitive identification of LKB1 deletions, which account for approximately50% of mutations in lung and cervical cancer (this and other studies) [9]. Another factor potentially obscuring prior sequence analyses is the unusually high GC content of LKB1 exonic regions. In our experience, automated base call software overlooked a high percentage of mutations, necessitating direct inspection of chromatograms.
###end p 30
###begin p 31
###xml 30 34 30 34 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LKB1</italic>
###xml 284 292 284 292 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 383 385 383 385 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">th</sup>
###xml 394 398 394 398 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005137-Masters1">[25]</xref>
###xml 742 746 742 746 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005137-Jones1">[26]</xref>
###xml 748 752 748 752 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005137-Jones2">[27]</xref>
###xml 754 758 754 758 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005137-Hsu1">[28]</xref>
###xml 835 839 835 839 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LKB1</italic>
###xml 1023 1027 1023 1027 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LKB1</italic>
###xml 1129 1132 1129 1132 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005137-Ji1">[9]</xref>
###xml 1134 1138 1134 1138 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005137-Tiainen1">[19]</xref>
###xml 230 235 <span type="species:ncbi:9606">human</span>
###xml 682 689 <span type="species:ncbi:9606">patient</span>
The discovery of a homozygous LKB1 deletion in HeLa is noteworthy because of the historical significance of this cell line to biomedical research. HeLa was derived in 1951 from a cervical adenocarcinoma. As the first immortalized human cell line isolated and successfully perpetuated in vitro, HeLa greatly accelerated the progress of biomedical research in the second half of the 20th century [25]. HeLa cells were unusual in growing so rapidly in culture, but the primary tumor was also aggressive. The primary tumor was confined to the cervix at the time of diagnosis, but it metastasized early and widely despite aggressive therapy including radiation treatment, leading to the patient's death just six months after the initial diagnosis [26], [27], [28]. Our results suggest that the homozygous deletion we have documented within LKB1 contributed to this aggressive growth phenotype, rationalizing some of the unusual features of the HeLa primary tumor and cell line. Consistent with this idea, enforced expression of LKB1 cDNA into HeLa and other HeLa-deficient cell lines induces growth arrest (unpublished data, see also [9], [19]).
###end p 31
###begin p 32
###xml 35 39 35 39 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LKB1</italic>
###xml 188 192 188 192 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LKB1</italic>
###xml 288 293 288 293 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">K-ras</italic>
###xml 330 334 330 334 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Lkb1</italic>
###xml 487 490 487 490 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p53</italic>
###xml 495 504 495 504 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ink4a/Arf</italic>
###xml 531 535 531 535 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Lkb1</italic>
###xml 663 667 663 667 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LKB1</italic>
###xml 745 748 745 748 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005137-Ji1">[9]</xref>
###xml 796 800 796 800 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Lkb1</italic>
###xml 929 933 929 933 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005137-Contreras1">[11]</xref>
###xml 975 979 975 979 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005137-Gurumurthy1">[12]</xref>
###xml 981 985 981 985 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005137-Pearson1">[29]</xref>
###xml 1176 1180 1176 1180 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LKB1</italic>
###xml 1239 1242 1239 1242 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005137-Ji1">[9]</xref>
###xml 92 97 <span type="species:ncbi:9606">human</span>
###xml 172 177 <span type="species:ncbi:10090">mouse</span>
###xml 301 306 <span type="species:ncbi:10090">mouse</span>
###xml 761 765 <span type="species:ncbi:10090">mice</span>
This is also the first report that LKB1 mutations confer a worse prognosis for a particular human cancer. However, this observations is in line with genetically-engineered mouse models of LKB1 deficiency that have consistently found that Lkb1 loss promotes invasive/metastatic growth. In K-ras driven mouse models of lung cancer, Lkb1 inactivation provided the strongest cooperation in terms of tumor latency and frequency of metastasis (as compared to classic tumor suppressors such as p53 and Ink4a/Arf). It is also notable that Lkb1 loss in the lung was associated with a broad histologic spectrum (squamous cell carcinomas to adenocarcinomas), recalling that LKB1 inactivation characterizes cervical carcinomas of varied histologic subtypes [9]. Similarly, mice with targeted inactivation of Lkb1 in endometrial epithelium develop highly invasive (yet paradoxically extremely well-differentiated) endometrial adenocarcinomas [11]. Taken together, these and other results [12], [29] argue that LKB1 suppresses invasion and metastasis and suggest that assays based on LKB1 may prove useful for prognostication in a variety of cancers. It will be of interest to determine if LKB1 mutations are also useful prognostically in other cancers [9].
###end p 32
###begin p 33
###xml 54 57 54 57 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005137-Steben1">[2]</xref>
###xml 152 156 152 156 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LKB1</italic>
###xml 215 219 215 219 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005137-Boshart1">[30]</xref>
###xml 233 237 233 237 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LKB1</italic>
###xml 312 319 312 319 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in situ</italic>
###xml 396 400 396 400 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LKB1</italic>
###xml 425 432 425 432 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in situ</italic>
###xml 962 966 962 966 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005137-Hezel1">[31]</xref>
###xml 1178 1182 1178 1182 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LKB1</italic>
###xml 46 49 <span type="species:ncbi:10566">HPV</span>
###xml 197 200 <span type="species:ncbi:10566">HPV</span>
###xml 242 245 <span type="species:ncbi:10566">HPV</span>
###xml 272 275 <span type="species:ncbi:10566">HPV</span>
###xml 677 680 <span type="species:ncbi:10566">HPV</span>
###xml 1135 1140 <span type="species:ncbi:9606">women</span>
The fact that 99% of cervical cancers contain HPV DNA [2] as is the case for most of the cervical cancer cell lines in which we demonstrated homozygous LKB1 deletions (e.g. HeLa harbors integrated HPV-18 sequences) [30] suggest that LKB1 and HPV cooperate in some manner. HPV infection promotes the formation of in situ lesions, leading us to propose that additional mutations in genes including LKB1 are required to convert in situ dysplasias to invasive carcinomas, an idea consistent with the diverse animal models discussed above. Further studies i.e. with genetically-engineered animal models will be required to understand the biological basis of the interaction between HPV and LKB1. The biological and biochemical basis of LKB1-mediated carcinogenesis remains to be fully elucidated. Misregulation of the AMPK-mTOR pathway likely contributes to LKB1's role as a tumor suppressor, but probably does not entirely account for its role in mediating invasion [31]. Nonetheless, misregulation of mTOR in LKB1-deficient tumors may present opportunities for targeted therapy (e.g. through the use of metformin or rapamycin analogs) in women whose cervical tumors have confirmed LKB1 mutations/deletions, an idea that merits further investigation in the future.
###end p 33
###begin p 34
###xml 43 46 <span type="species:ncbi:10566">HPV</span>
The biological basis of the progression of HPV-induced precancers has been undefined. This study presents the first definitive evidence that recurring mutations in discrete host genes occur in invasive cervical cancer. Although other factors likely influence progression, this study demonstrates that a process likely to be stochastic-namely the acquisition of discrete genetic mutations-drives progression of cervical dysplasias to invasive lethal carcinomas and that these mutations have the potential to serve as useful prognosticators.
###end p 34
###begin title 35
Materials and Methods
###end title 35
###begin title 36
Ethics Statement
###end title 36
###begin p 37
This study was conducted according to the principles expressed in the Declaration of Helsinki. The study was approved by the Institutional Review Board of the UT Southwestern and Johns Hopkins hospitals.
###end p 37
###begin title 38
###xml 0 7 <span type="species:ncbi:9606">Patient</span>
Patient Samples and Cell Lines
###end title 38
###begin p 39
###xml 231 234 231 234 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005137-Crum1">[4]</xref>
###xml 4 12 <span type="species:ncbi:9606">patients</span>
###xml 32 40 <span type="species:ncbi:9606">patients</span>
###xml 417 425 <span type="species:ncbi:9606">patients</span>
###xml 486 494 <span type="species:ncbi:9606">patients</span>
###xml 745 753 <span type="species:ncbi:9606">patients</span>
###xml 979 987 <span type="species:ncbi:9606">patients</span>
The patients were a subgroup of patients diagnosed with primary cervical cancer at UT Southwestern University Hospitals between 2000-2007 and who provided informed consent. Histopathologic diagnoses were made per standard criteria [4]. Sufficient amounts of tissue from the primary tumor had to be available to permit the isolation of DNA for sequencing and MLPA; otherwise there were no exclusion criteria. For most patients, control DNA was prepared from blood; for a small number of patients for whom blood was unavailable, DNA was prepared from paraffin-embedded control tissues. Tumor stage was determined per FIGO criteria. Data for disease progression analysis per RECIST criteria were obtained from follow-up visits. We recommended that patients have follow-up visits every 3 months for 2 years, then every 6 months for 3 years, and annually thereafter. For progression-free survival, time from completion of primary therapy to recurrence or death was recorded. Data for patients without tumor recurrence were censored at the time of the last follow-up visit. For the HeLa tumor study, a paraffin block was obtained from the archives of the Johns Hopkins Hospital. Cell lines were purchased from the ATCC.
###end p 39
###begin title 40
DNA Sequencing
###end title 40
###begin p 41
DNA was prepared using Qiagen genomic DNA columns. A two step "boost/nest" PCR strategy was employed where the boost reaction generated a larger fragment used as a template for the nest reaction. The nest products were bidirectionally sequenced on ABI 3730 XL sequencers with ABI Big Dye Terminator 3.1 chemistry. Base calling was performed with the Agent system (Paracel). Sequence tracings were visually inspected to confirm accurate variant detection by the base-calling software. PCR primer sequences/conditions are available upon request. Coding variants were confirmed on repeat PCR reactions to exclude PCR artifacts. Genbank NM_000455 was used as the reference cDNA for nucleotide positions.
###end p 41
###begin title 42
Multiplex Ligation Dependent Probe Amplification (MLPA) and Southern/Western Analysis
###end title 42
###begin p 43
###xml 32 35 32 35 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005137-Ji1">[9]</xref>
###xml 86 90 82 86 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">XbaI</italic>
MLPA was performed as described [9]. For Southern analysis, 10 microg genomic DNA was XbaI-digested prior to gel electrophoresis, transferred to a membrane, and hybridized with radiolabelled-probes (1-2 kb) generated by PCR and confirmed by end-sequencing. The membrane was hybridized to probe A, subjected to autoradiography, stripped in boiling 0.1% SDS, and rehybridized to probe B. For Western analysis, protein extracts were prepared from adherent cells by homogenization in lysis buffer+protease inhibitors on ice, subjected to SDS-PAGE and immunoblotted with an LKB1 antibody (#3047, Cell Signalling Technology) per the manufacturer's recommendations.
###end p 43
###begin title 44
Tissue Staining and Immunohistochemistry
###end title 44
###begin p 45
Paraffin block 5 microm sections were deparaffinized/ hydrated in an ethanol series. Slides were stained with H&E and mucicarmine per standard protocols. For immunohistochemistry, slides were subjected to antigen retrieval in boiling in 10 mM NaCitrate; p63 antibody (#MS1081, LabVision) was used at 1:400 with the Immpress detection system (Vector).
###end p 45
###begin title 46
PCR Scanning to Define Deletions and HeLa-specific PCR
###end title 46
###begin p 47
###xml 58 62 58 62 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LKB1</italic>
###xml 526 530 526 530 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005137-Bonin1">[32]</xref>
###xml 589 615 589 615 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;-GGTTGCGATCAAGGCCCCGA-3&#8242;</named-content>
###xml 625 651 625 651 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;-GCCTGTGGATGCCACACATG-3&#8242;</named-content>
###xml 159 164 <span type="species:ncbi:9606">human</span>
PCR primers (producing 100-200 bp amplicons) spanning the LKB1 region were designed using Primer3. Primer pairs producing products of correct size when normal human DNA was used as template were used to map deletions by scoring presence/absence of amplification with cell line DNAs as template. Additional reactions to give products corresponding to progressively smaller intervals were designed as necessary. Primer sequences and PCR conditions are available upon request. Archival tissue block DNA was prepared as described [32]. Primer sequences for HeLa-specific PCR (400 bp) were For(5'-GGTTGCGATCAAGGCCCCGA-3') and Rev(5'-GCCTGTGGATGCCACACATG-3'). PCR conditions were 95Cx10'; 94Cx30'', 58Cx30'', 72Cx30'' (38 cycles); 72Cx7'.
###end p 47
###begin title 48
Statistical Analysis
###end title 48
###begin p 49
For comparison of mutant frequencies, Fisher's (two-tailed) unpaired exact test was used. Survival curves were generated in GraphPad Prism5, with comparison of the curves performed with the Log-rank (Mantel-Cox) test. The hazard ratio and its confidence interval were computed using the Mantel-Haenszel method. P values less than 0.05 were considered to indicate statistical significance.
###end p 49
###begin title 50
Supporting Information
###end title 50
###begin p 51
###xml 32 36 32 36 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LKB1</italic>
###xml 766 770 754 758 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LKB1</italic>
###xml 866 870 854 858 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LKB1</italic>
###xml 1046 1055 1034 1043 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005137-g004">Figure 4C</xref>
###xml 658 663 <span type="species:ncbi:9606">human</span>
Cloning and characterization of LKB1 intragenic deletion breakpoints in HeLa/HeLaS3. A 2.8 kb fragment spanning the deletion breakpoint was cloned from HeLa DNA by PCR as described in the text; 974 bp of this sequence are shown. Sequence in bold red letters corresponds to the Alu repeat in which the presumptive homologous recombination event resulting in the HeLa deletion occurred. Nucleotide polymorphisms in the two native Alu sequences (not shown) were consistent with a recombination event occurring within the 5 bp boxed sequence (i.e., the flanking G bases were polymorphic and informative). Sequence in blue corresponds to a unique sequence in the human genome (Ensembl 50 19:1145482 to 1145865). This sequence is approximately11 kb from the 5' end of the LKB1 gene (transcriptional start). Sequence in green (Ensembl 50 19:1170845 to 1171115) lies within LKB1 intron 3-4. The arrows show the location of the primers designed for HeLa-specific PCR (400 bp amplicon). The genomic location of these primers on the genomic map is shown in Figure 4C.
###end p 51
###begin p 52
(0.01 MB PDF)
###end p 52
###begin p 53
Click here for additional data file.
###end p 53
###begin p 54
Complete list of LKB1 mutations detected by sequencing or MLPA.
###end p 54
###begin p 55
(0.01 MB PDF)
###end p 55
###begin p 56
Click here for additional data file.
###end p 56
###begin p 57
We are indebted to Grover Hutchins (Johns Hopkins University School of Medicine) and Juanita Valenciana (UT Southwestern) for assistance with specimen procurement and technical advice. We also thank Jennifer Sayne and the UT Southwestern Tissue Management Resource of the Simmons Comprehensive Cancer Center for assistance with specimen procurement and clinical information management.
###end p 57
###begin title 58
References
###end title 58
###begin article-title 59
Epidemiology and biology of cervical cancer.
###end article-title 59
###begin article-title 60
###xml 0 20 <span type="species:ncbi:10566">Human papillomavirus</span>
Human papillomavirus infection: epidemiology and pathophysiology.
###end article-title 60
###begin article-title 61
Focus on endometrial and cervical cancer.
###end article-title 61
###begin article-title 62
Liquid compared with conventional cervical cytology: a systematic review and meta-analysis.
###end article-title 62
###begin article-title 63
Characterization of naturally occurring HPV16 integration sites isolated from cervical keratinocytes under noncompetitive conditions.
###end article-title 63
###begin article-title 64
###xml 26 31 <span type="species:ncbi:9606">human</span>
Condylomata acuminata and human genital cancer.
###end article-title 64
###begin article-title 65
Lkb1-dependent signaling pathways.
###end article-title 65
###begin article-title 66
LKB1 modulates lung cancer differentiation and metastasis.
###end article-title 66
###begin article-title 67
Prevalence and specificity of LKB1 genetic alterations in lung cancers.
###end article-title 67
###begin article-title 68
Loss of Lkb1 provokes highly invasive endometrial adenocarcinomas.
###end article-title 68
###begin article-title 69
###xml 27 31 <span type="species:ncbi:10090">mice</span>
LKB1 deficiency sensitizes mice to carcinogen-induced tumorigenesis.
###end article-title 69
###begin article-title 70
Frequency and spectrum of cancers in the Peutz-Jeghers syndrome.
###end article-title 70
###begin article-title 71
###xml 100 108 <span type="species:ncbi:9606">patients</span>
Functional analysis of LKB1/STK11 mutants and two aberrant isoforms found in Peutz-Jeghers Syndrome patients.
###end article-title 71
###begin article-title 72
###xml 85 93 <span type="species:ncbi:9606">patients</span>
Loss of cytoplasmic retention ability of mutant LKB1 found in Peutz-Jeghers syndrome patients.
###end article-title 72
###begin article-title 73
No evidence of Peutz-Jeghers syndrome gene LKB1 involvement in left-sided colorectal carcinomas.
###end article-title 73
###begin article-title 74
Loss of the Lkb1 tumour suppressor provokes intestinal polyposis but resistance to transformation.
###end article-title 74
###begin article-title 75
Endocervical adenocarcinoma and its variants: their morphology and differential diagnosis.
###end article-title 75
###begin article-title 76
Growth suppression by Lkb1 is mediated by a G(1) cell cycle arrest.
###end article-title 76
###begin article-title 77
Epigenetic inactivation of LKB1 in primary tumors associated with the Peutz-Jeghers syndrome.
###end article-title 77
###begin article-title 78
A Rapid Method for Viable Cell Titration and Clone Production with Hela Cells in Tissue Culture: The Use of X-Irradiated Cells to Supply Conditioning Factors.
###end article-title 78
###begin article-title 79
Tissue culture studies of the proliferative capacity of cervical carcinoma and normal epithelium.
###end article-title 79
###begin article-title 80
Somatic mutations in the STK11/LKB1 gene are uncommon in rare gynecological tumor types associated with Peutz-Jegher's syndrome.
###end article-title 80
###begin article-title 81
LKB1 somatic mutations in sporadic tumors.
###end article-title 81
###begin article-title 82
HeLa cells 50 years on: the good, the bad and the ugly.
###end article-title 82
###begin article-title 83
Record of the first physician to see Henrietta Lacks at the Johns Hopkins Hospital: history of the beginning of the HeLa cell line.
###end article-title 83
###begin article-title 84
George Otto Gey. (1899-1970). The HeLa cell and a reappraisal of its origin.
###end article-title 84
###begin article-title 85
Genetic characteristics of the HeLa cell.
###end article-title 85
###begin article-title 86
###xml 49 54 <span type="species:ncbi:10090">mouse</span>
Lkb1 deficiency causes prostate neoplasia in the mouse.
###end article-title 86
###begin article-title 87
A new type of papillomavirus DNA, its presence in genital cancer biopsies and in cell lines derived from cervical cancer.
###end article-title 87
###begin article-title 88
LKB1; linking cell structure and tumor suppression.
###end article-title 88
###begin article-title 89
DNA and RNA obtained from Bouin's fixed tissues.
###end article-title 89
###begin p 90
###xml 0 21 0 21 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Competing Interests: </bold>
Competing Interests: The authors have declared that no competing interests exist.
###end p 90
###begin p 91
###xml 0 9 0 9 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Funding: </bold>
Funding: This work was funded through Sidney Kimmel Translational Science Awards to D.H.C., K.K.W., N.B., and N.E.S., an NIH NRSA F31 fellowship to C.M.C., a Young Investigator Award from the American Cancer Society/UT Southwestern Simmons Comprehensive Cancer Center to D.H.C, and the National Center for Research Resources (K26RR024196) (D.H.C.). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
###end p 91

